Gilead CEO: We can manufacture enough remdesivir to provide to all of the U.S.

Gilead Sciences CEO Daniel O'Day told CNBC's "Squawk Box" Friday that Gilead can now supply remdesivir to any hospitalized patient in the U.S. and will be able to satisfy global demand by the end of October.
Fri, Oct 9 20208:10 AM EDT